MSC-Exo treatment modulated NF-κB and phosphoinositide 3-kinase/protein kinase B (PI3K/Akt) signaling pathways by inhibiting tumor TNF-associated factor 1 expression and enhancing macrophage M2 polarization [34]. The gene discussed is AKT1; the disease is neoplasm.